Vietnam’s Pharmaceutical Market Value to Hit $8 Billion by 2020

The pharmaceutical market in Vietnam is set to increase in value by $5 billion over the next 6 years, reaching a net worth of $8 billion by 2020 and representing an impressive Compound Annual Growth Rate (CAGR) of 15.4%, says research and consulting firm GlobalData.

The company’s latest report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Vietnam, states that the scarcity of low-priced generic drugs, combined with a belief among Vietnamese doctors that patent-protected branded drugs are more effective, means that foreign pharmaceutical companies dominate the market and are able to maintain premium revenue.

In 2005, innovator drug prices in Vietnam were 8.3 times higher than international reference prices. Although 2009 saw the Vietnamese government introduce the New Health Insurance Law for universal coverage by 2020, as well as make it a legal requirement for all of its pharmaceutical production facilities to operate with Good Manufacturing Practice certificates, prospects for generic and locally manufactured drugs remain limited.

“A preoccupation with generic drugs and low investment in research and development means that domestic pharmaceutical companies are at a distinct disadvantage when competing against imports from multinationals,” said Joshua Owide, GlobalData’s Director of Healthcare Industry.

This is despite the fact that Vietnam is one of the fastest growing economies in the Southeast Asia region, with its Gross Domestic Product (GDP) having increased significantly in value from $101.6 billion in 2008 to an estimated $170.6 billion in 2013.
The Drug Administration of Vietnam issues a new drug registration within 180 days of an application being submitted. This makes the process much quicker than in the US and UK, although it is in line with other countries in Southeast Asia.

However, there are some obstacles that pharmaceutical manufacturers must face when launching new products into Vietnam’s pharmaceutical marketplace.

“While the time taken to evaluate new and generic drug approvals is shorter than in developed countries, the application submission procedure is rigorous,” explained Owide.

Extra documentation is required, as is the mandatory submission of certain data in Vietnamese. This makes it more difficult for new products to enter this arena and will subsequently hinder any further market growth over the forecast period.”

The report provides information on and analysis of the healthcare, regulatory, and reimbursement landscape in Vietnam, identifying key trends in the healthcare market and providing insights into the demographic, regulatory, reimbursement landscape, and healthcare infrastructure. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Its research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling them to offer the most relevant, reliable, and actionable strategic business intelligence available for a wide range of industries. For more information, www.globaldata.com.